^
    Back
    Association details:
    Biomarker:ATM PI2629fs*
    Cancer:Endometrial Cancer
    Drug:elimusertib (BAY 1895344) (ATR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

    Published date:
    09/28/2020
    Excerpt:
    ...oral ATR inhibitor BAY 1895344 intermittently dosed 5–80 mg twice daily (BID)...1 patient with endometrial cancer at 80 mg BID 3 days on/4 days off) and had RECIST partial responses.. Responders had ATM protein loss and/or deleterious ATM mutations and received doses 40 mg BID....endometrial cancer and had loss of ATM protein expression in an archival baseline biopsy and an ATM deleterious mutation (ATM_p.I2629fs*) with allele frequency of 40%.
    DOI:
    10.1158/2159-8290.CD-20-0868